$BMRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BIOMARIN PHARMACEUTICAL INC. Get notifications about new insider transactions in BIOMARIN PHARMACEUTICAL INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 23 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 37.46 | 1,000 | 37,460 | 138,000 | |
| Jun 23 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 37.46 | 1,000 | 37,460 | 304,839 | 303.8 K to 304.8 K (+0.33 %) |
| May 27 2021 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Grant | A | 0.00 | 5,120 | 0 | 23,970 | 18.9 K to 24 K (+27.16 %) |
| May 27 2021 | BMRN | BIOMARIN PHARMACEU ... | HOMBACH ROBERT J. | Director | Grant | A | 0.00 | 5,120 | 0 | 21,330 | 16.2 K to 21.3 K (+31.59 %) |
| May 27 2021 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Grant | A | 0.00 | 5,120 | 0 | 72,088 | 67 K to 72.1 K (+7.65 %) |
| May 12 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 8,513 | 225,509 | 0 | |
| May 12 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 77.29 | 8,513 | 657,970 | 303,839 | 312.4 K to 303.8 K (-2.73 %) |
| May 12 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 8,513 | 225,509 | 312,352 | 303.8 K to 312.4 K (+2.80 %) |
| May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | M | 28.23 | 6,709 | 189,395 | 0 | |
| May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Sell | S | 79.50 | 6,709 | 533,366 | 31,357 | 38.1 K to 31.4 K (-17.62 %) |
| May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Buy | M | 28.23 | 6,709 | 189,395 | 38,066 | 31.4 K to 38.1 K (+21.40 %) |
| May 11 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 62.41 | 341 | 21,281 | 31,357 | 31 K to 31.4 K (+1.10 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 25,000 | 662,250 | 8,513 | |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 25,000 | 662,250 | 33,513 | |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 79.39 | 3,329 | 264,303 | 303,839 | 307.2 K to 303.8 K (-1.08 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 78.77 | 6,115 | 481,672 | 307,168 | 313.3 K to 307.2 K (-1.95 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 77.60 | 15,556 | 1,207,146 | 313,283 | 328.8 K to 313.3 K (-4.73 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 25,000 | 662,250 | 328,839 | 303.8 K to 328.8 K (+8.23 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 78.69 | 10,175 | 800,671 | 303,839 | 314 K to 303.8 K (-3.24 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 78.01 | 14,825 | 1,156,528 | 314,014 | 328.8 K to 314 K (-4.51 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 25,000 | 662,250 | 328,839 | 303.8 K to 328.8 K (+8.23 %) |
| May 10 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 62.41 | 341 | 21,281 | 303,839 | 303.5 K to 303.8 K (+0.11 %) |
| May 07 2021 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Option Exercise | M | 26.49 | 15,000 | 397,350 | 0 | |
| May 07 2021 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Sell | S | 78.38 | 5,068 | 397,245 | 94,272 | 99.3 K to 94.3 K (-5.10 %) |
| May 07 2021 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Buy | M | 26.49 | 15,000 | 397,350 | 99,340 | 84.3 K to 99.3 K (+17.79 %) |
| May 05 2021 | BMRN | BIOMARIN PHARMACEU ... | Guyer Charles Greg | EVP, Chief Technica ... | Payment of Exercise | F | 78.35 | 3,986 | 312,303 | 41,695 | 45.7 K to 41.7 K (-8.73 %) |
| May 05 2021 | BMRN | BIOMARIN PHARMACEU ... | Guyer Charles Greg | EVP, Chief Technica ... | Grant | A | 62.41 | 221 | 13,792 | 45,681 | 45.5 K to 45.7 K (+0.49 %) |
| May 04 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 78.30 | 2,089 | 163,569 | 64,108 | 66.2 K to 64.1 K (-3.16 %) |
| May 04 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 78.30 | 2,584 | 202,327 | 66,197 | 68.8 K to 66.2 K (-3.76 %) |
| May 04 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 62.41 | 341 | 21,281 | 68,781 | 68.4 K to 68.8 K (+0.50 %) |
| May 03 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 37.46 | 1,000 | 37,460 | 139,000 | |
| May 03 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 37.46 | 1,000 | 37,460 | 303,498 | 302.5 K to 303.5 K (+0.33 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 10,000 | 264,900 | 58,513 | |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 10,000 | 264,900 | 68,513 | |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 10,000 | 264,900 | 58,513 | |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 79.34 | 10,000 | 793,400 | 302,498 | 312.5 K to 302.5 K (-3.20 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 10,000 | 264,900 | 68,513 | |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 10,000 | 264,900 | 312,498 | 302.5 K to 312.5 K (+3.31 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 79.34 | 10,000 | 793,400 | 302,498 | 312.5 K to 302.5 K (-3.20 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 78.91 | 10,000 | 789,100 | 302,498 | 312.5 K to 302.5 K (-3.20 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 10,000 | 264,900 | 312,498 | 302.5 K to 312.5 K (+3.31 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 10,000 | 264,900 | 312,498 | 302.5 K to 312.5 K (+3.31 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 78.91 | 10,000 | 789,100 | 302,498 | 312.5 K to 302.5 K (-3.20 %) |
| Apr 26 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 10,000 | 264,900 | 312,498 | 302.5 K to 312.5 K (+3.31 %) |
| Apr 20 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | M | 26.49 | 2,709 | 71,761 | 0 | |
| Apr 20 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 79.58 | 2,709 | 215,582 | 68,440 | 71.1 K to 68.4 K (-3.81 %) |
| Apr 20 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Buy | M | 26.49 | 2,709 | 71,761 | 71,149 | 68.4 K to 71.1 K (+3.96 %) |
| Apr 20 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | M | 26.49 | 2,709 | 71,761 | 0 | |
| Apr 20 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 79.58 | 2,709 | 215,582 | 68,440 | 71.1 K to 68.4 K (-3.81 %) |
| Apr 20 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Buy | M | 26.49 | 2,709 | 71,761 | 71,149 | 68.4 K to 71.1 K (+3.96 %) |
| Apr 19 2021 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 26.49 | 7,500 | 198,675 | 0 | |
| Apr 19 2021 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 76.90 | 7,500 | 576,750 | 18,850 | 26.4 K to 18.9 K (-28.46 %) |
| Apr 19 2021 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 26.49 | 7,500 | 198,675 | 26,350 | 18.9 K to 26.4 K (+39.79 %) |
| Apr 09 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 78.81 | 1,537 | 121,131 | 58,250 | 59.8 K to 58.3 K (-2.57 %) |
| Apr 02 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Sell | S | 76.30 | 5,692 | 434,300 | 31,016 | 36.7 K to 31 K (-15.51 %) |
| Apr 01 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 74.79 | 1,652 | 123,553 | 59,787 | 61.4 K to 59.8 K (-2.69 %) |
| Mar 26 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 76.30 | 1,181 | 90,110 | 61,439 | 62.6 K to 61.4 K (-1.89 %) |
| Mar 26 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 76.30 | 1,181 | 90,110 | 61,439 | 62.6 K to 61.4 K (-1.89 %) |
| Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 78.52 | 516 | 40,516 | 36,708 | 37.2 K to 36.7 K (-1.39 %) |
| Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 78.52 | 2,454 | 192,688 | 106,142 | 108.6 K to 106.1 K (-2.26 %) |
| Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 78.52 | 1,391 | 109,221 | 68,440 | 69.8 K to 68.4 K (-1.99 %) |
| Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 78.52 | 5,519 | 433,352 | 302,498 | 308 K to 302.5 K (-1.79 %) |
| Mar 23 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 78.52 | 1,513 | 118,801 | 62,620 | 64.1 K to 62.6 K (-2.36 %) |
| Mar 19 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 77.99 | 1,308 | 102,011 | 64,133 | 65.4 K to 64.1 K (-2.00 %) |
| Mar 19 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 77.99 | 1,308 | 102,011 | 64,133 | 65.4 K to 64.1 K (-2.00 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Guyer Charles Greg | EVP, Chief Technica ... | Option Exercise | A | 78.39 | 25,650 | 2,010,704 | 25,650 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Guyer Charles Greg | EVP, Chief Technica ... | Grant | A | 0.00 | 10,420 | 0 | 45,460 | 35 K to 45.5 K (+29.74 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Option Exercise | A | 78.39 | 24,890 | 1,951,127 | 24,890 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 77.21 | 582 | 44,936 | 37,224 | 37.8 K to 37.2 K (-1.54 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 78.39 | 994 | 77,920 | 37,806 | 38.8 K to 37.8 K (-2.56 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Grant | A | 0.00 | 10,110 | 0 | 38,800 | 28.7 K to 38.8 K (+35.24 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 78.39 | 25,650 | 2,010,704 | 25,650 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 77.21 | 1,252 | 96,667 | 69,831 | 71.1 K to 69.8 K (-1.76 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 78.39 | 5,014 | 393,047 | 71,083 | 76.1 K to 71.1 K (-6.59 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 10,420 | 0 | 76,097 | 65.7 K to 76.1 K (+15.87 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 78.39 | 37,710 | 2,956,087 | 37,710 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 77.21 | 2,259 | 174,417 | 108,596 | 110.9 K to 108.6 K (-2.04 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 78.39 | 7,460 | 584,789 | 110,855 | 118.3 K to 110.9 K (-6.31 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 15,320 | 0 | 118,315 | 103 K to 118.3 K (+14.87 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 78.39 | 26,400 | 2,069,496 | 26,400 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 77.21 | 1,287 | 99,369 | 65,441 | 66.7 K to 65.4 K (-1.93 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 78.39 | 5,273 | 413,350 | 66,728 | 72 K to 66.7 K (-7.32 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 10,720 | 0 | 72,001 | 61.3 K to 72 K (+17.49 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 78.39 | 101,820 | 7,981,670 | 101,820 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 77.21 | 5,559 | 429,210 | 308,017 | 313.6 K to 308 K (-1.77 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 78.39 | 23,426 | 1,836,364 | 313,576 | 337 K to 313.6 K (-6.95 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 41,350 | 0 | 337,002 | 295.7 K to 337 K (+13.99 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Acosta Andrea | GVP, Chief Accounti ... | Option Exercise | A | 78.39 | 5,280 | 413,899 | 5,280 | |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Acosta Andrea | GVP, Chief Accounti ... | Payment of Exercise | F | 77.21 | 379 | 29,263 | 18,136 | 18.5 K to 18.1 K (-2.05 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Acosta Andrea | GVP, Chief Accounti ... | Payment of Exercise | F | 78.39 | 553 | 43,350 | 18,515 | 19.1 K to 18.5 K (-2.90 %) |
| Mar 17 2021 | BMRN | BIOMARIN PHARMACEU ... | Acosta Andrea | GVP, Chief Accounti ... | Grant | A | 0.00 | 4,290 | 0 | 19,068 | 14.8 K to 19.1 K (+29.03 %) |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 7,000 | 185,430 | 78,513 | |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 7,000 | 185,430 | 85,513 | |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 77.10 | 7,000 | 539,700 | 295,652 | 302.7 K to 295.7 K (-2.31 %) |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 7,000 | 185,430 | 302,652 | 295.7 K to 302.7 K (+2.37 %) |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 77.68 | 7,000 | 543,760 | 295,652 | 302.7 K to 295.7 K (-2.31 %) |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 7,000 | 185,430 | 302,652 | 295.7 K to 302.7 K (+2.37 %) |
| Mar 15 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | L | 77.94 | 100 | 7,794 | 295,652 | 295.6 K to 295.7 K (+0.03 %) |
| Feb 22 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 7,000 | 185,430 | 92,513 | |
| Feb 22 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.58 | 7,000 | 585,060 | 295,552 | 302.6 K to 295.6 K (-2.31 %) |
| Feb 22 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 7,000 | 185,430 | 302,552 | 295.6 K to 302.6 K (+2.37 %) |
| Feb 19 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 7,000 | 185,430 | 99,513 | |
| Feb 19 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 85.08 | 7,000 | 595,560 | 295,552 | 302.6 K to 295.6 K (-2.31 %) |
| Feb 19 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 7,000 | 185,430 | 302,552 | 295.6 K to 302.6 K (+2.37 %) |
| Feb 19 2021 | BMRN | BIOMARIN PHARMACEU ... | Ho Maykin | Director | Grant | A | 0.00 | 2,350 | 0 | 2,350 | 0 to 2.4 K |
| Feb 18 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 8,000 | 211,920 | 106,513 | |
| Feb 18 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.54 | 8,000 | 676,320 | 295,552 | 303.6 K to 295.6 K (-2.64 %) |
| Feb 18 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 8,000 | 211,920 | 303,552 | 295.6 K to 303.6 K (+2.71 %) |
| Feb 04 2021 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | EVP, Chief Financia ... | Payment of Exercise | F | 82.82 | 1,071 | 88,700 | 28,673 | 29.7 K to 28.7 K (-3.60 %) |
| Feb 01 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 8,334 | 220,768 | 114,513 | |
| Feb 01 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 8,333 | 220,741 | 122,847 | |
| Feb 01 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.67 | 8,334 | 688,972 | 295,552 | 303.9 K to 295.6 K (-2.74 %) |
| Feb 01 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 8,334 | 220,768 | 303,886 | 295.6 K to 303.9 K (+2.82 %) |
| Feb 01 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.91 | 8,333 | 690,889 | 295,552 | 303.9 K to 295.6 K (-2.74 %) |
| Feb 01 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 8,333 | 220,741 | 303,885 | 295.6 K to 303.9 K (+2.82 %) |
| Jan 28 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 26.49 | 8,333 | 220,741 | 131,180 | |
| Jan 28 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 85.49 | 8,333 | 712,388 | 295,552 | 303.9 K to 295.6 K (-2.74 %) |
| Jan 28 2021 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 26.49 | 8,333 | 220,741 | 303,885 | 295.6 K to 303.9 K (+2.82 %) |
| Dec 30 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.18 | 1,500 | 132,270 | 295,552 | 297.1 K to 295.6 K (-0.50 %) |
| Dec 30 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.77 | 1,500 | 133,155 | 297,052 | 298.6 K to 297.1 K (-0.50 %) |
| Dec 30 2020 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Gift | G | 0.00 | 425 | 0 | 247,533 | 248 K to 247.5 K (-0.17 %) |
| Oct 15 2020 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.91 | 2,121 | 169,489 | 61,281 | 63.4 K to 61.3 K (-3.35 %) |
| Oct 08 2020 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Option Exercise | M | 26.49 | 15,000 | 397,350 | 0 | |
| Oct 08 2020 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Option Exercise | M | 26.49 | 15,000 | 397,350 | 0 | |
| Oct 08 2020 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Buy | M | 26.49 | 15,000 | 397,350 | 66,968 | 52 K to 67 K (+28.86 %) |
| Oct 08 2020 | BMRN | BIOMARIN PHARMACEU ... | HERON ELAINE J | Director | Buy | M | 26.49 | 15,000 | 397,350 | 66,968 | 52 K to 67 K (+28.86 %) |
| Sep 01 2020 | BMRN | BIOMARIN PHARMACEU ... | PYOTT DAVID E I | Director | Buy | P | 78.84 | 900 | 70,955 | 30,740 | 29.8 K to 30.7 K (+3.02 %) |
| Sep 01 2020 | BMRN | BIOMARIN PHARMACEU ... | PYOTT DAVID E I | Director | Buy | P | 78.22 | 11,900 | 930,760 | 29,840 | 17.9 K to 29.8 K (+66.33 %) |
| Sep 01 2020 | BMRN | BIOMARIN PHARMACEU ... | PYOTT DAVID E I | Director | Buy | P | 78.84 | 900 | 70,955 | 30,740 | 29.8 K to 30.7 K (+3.02 %) |
| Sep 01 2020 | BMRN | BIOMARIN PHARMACEU ... | PYOTT DAVID E I | Director | Buy | P | 78.22 | 11,900 | 930,760 | 29,840 | 17.9 K to 29.8 K (+66.33 %) |
| Aug 05 2020 | BMRN | BIOMARIN PHARMACEU ... | GREY MICHAEL G | Director | Option Exercise | M | 26.49 | 2,500 | 66,225 | 5,000 | |
| Aug 05 2020 | BMRN | BIOMARIN PHARMACEU ... | GREY MICHAEL G | Director | Sell | S | 120.35 | 2,500 | 300,875 | 42,840 | 45.3 K to 42.8 K (-5.51 %) |
| Aug 05 2020 | BMRN | BIOMARIN PHARMACEU ... | GREY MICHAEL G | Director | Buy | M | 26.49 | 2,500 | 66,225 | 45,340 | 42.8 K to 45.3 K (+5.84 %) |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 63.10 | 49,423 | 3,118,591 | 0 | |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 67.81 | 75,716 | 5,134,302 | 0 | |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 67.81 | 1,250 | 84,763 | 0 | |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 130.00 | 126,389 | 16,430,570 | 102,995 | 229.4 K to 103 K (-55.10 %) |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 63.10 | 49,423 | 3,118,591 | 229,384 | 180 K to 229.4 K (+27.46 %) |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 67.81 | 75,716 | 5,134,302 | 179,961 | 104.2 K to 180 K (+72.63 %) |
| Jul 22 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 67.81 | 1,250 | 84,763 | 104,245 | 103 K to 104.2 K (+1.21 %) |
| Jul 21 2020 | BMRN | BIOMARIN PHARMACEU ... | Acosta Andrea | GVP, Chief Accounin ... | Payment of Exercise | F | 128.21 | 285 | 36,540 | 14,674 | 15 K to 14.7 K (-1.91 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 63.10 | 8,977 | 566,449 | 49,423 | |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 67.81 | 13,810 | 936,456 | 75,716 | |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 67.81 | 224 | 15,189 | 1,250 | |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 130.00 | 23,011 | 2,991,430 | 102,995 | 126 K to 103 K (-18.26 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 63.10 | 8,977 | 566,449 | 126,006 | 117 K to 126 K (+7.67 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 67.81 | 13,810 | 936,456 | 117,029 | 103.2 K to 117 K (+13.38 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 67.81 | 224 | 15,189 | 103,219 | 103 K to 103.2 K (+0.22 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 62.59 | 339 | 21,217 | 102,995 | 102.7 K to 103 K (+0.33 %) |
| Jul 15 2020 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 63.10 | 8,977 | 566,449 | 49,423 |